In a low percentage of triple-negative breast cancers, PI3K/AKT/mTOR pathway is activated, which lead to the hypothesis that inhibition of the PI3K signaling pathway may ensure a proper treatment for patients diagnosed with mesenchymal and luminal androgen receptor (LAR) types of TNBCs [43]. The gene discussed is AKT1; the disease is triple-negative breast carcinoma.